1. Home
  2. LQDA vs UMH Comparison

LQDA vs UMH Comparison

Compare LQDA & UMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • UMH
  • Stock Information
  • Founded
  • LQDA 2004
  • UMH 1968
  • Country
  • LQDA United States
  • UMH United States
  • Employees
  • LQDA N/A
  • UMH N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • UMH Real Estate Investment Trusts
  • Sector
  • LQDA Health Care
  • UMH Real Estate
  • Exchange
  • LQDA Nasdaq
  • UMH Nasdaq
  • Market Cap
  • LQDA 1.2B
  • UMH 1.4B
  • IPO Year
  • LQDA 2018
  • UMH N/A
  • Fundamental
  • Price
  • LQDA $19.60
  • UMH $16.81
  • Analyst Decision
  • LQDA Strong Buy
  • UMH Strong Buy
  • Analyst Count
  • LQDA 9
  • UMH 4
  • Target Price
  • LQDA $27.67
  • UMH $21.00
  • AVG Volume (30 Days)
  • LQDA 2.4M
  • UMH 484.1K
  • Earning Date
  • LQDA 08-06-2025
  • UMH 08-06-2025
  • Dividend Yield
  • LQDA N/A
  • UMH 5.35%
  • EPS Growth
  • LQDA N/A
  • UMH N/A
  • EPS
  • LQDA N/A
  • UMH 0.10
  • Revenue
  • LQDA $14,144,000.00
  • UMH $243,777,000.00
  • Revenue This Year
  • LQDA $189.27
  • UMH $6.95
  • Revenue Next Year
  • LQDA $402.79
  • UMH $7.07
  • P/E Ratio
  • LQDA N/A
  • UMH $161.85
  • Revenue Growth
  • LQDA N/A
  • UMH 8.17
  • 52 Week Low
  • LQDA $8.26
  • UMH $15.74
  • 52 Week High
  • LQDA $19.76
  • UMH $20.64
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 79.39
  • UMH 45.59
  • Support Level
  • LQDA $14.04
  • UMH $16.77
  • Resistance Level
  • LQDA $14.67
  • UMH $17.20
  • Average True Range (ATR)
  • LQDA 0.89
  • UMH 0.28
  • MACD
  • LQDA 0.70
  • UMH -0.01
  • Stochastic Oscillator
  • LQDA 97.88
  • UMH 26.67

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About UMH UMH Properties Inc.

UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.

Share on Social Networks: